Show simple item record

2018-10-01Zeitschriftenartikel DOI: 10.25646/5991
Profiling antimicrobial peptides from the medical maggot Lucilia sericata as potential antibiotics for MDR Gram-negative bacteria
dc.contributor.authorHirsch, Rolf
dc.contributor.authorWiesner, Jochen
dc.contributor.authorMarker, Alexander
dc.contributor.authorPfeifer, Yvonne
dc.contributor.authorBauer, Armin
dc.contributor.authorHammann, Peter E.
dc.contributor.authorVilcinskas, Andreas
dc.date.accessioned2019-03-22T09:00:21Z
dc.date.available2019-03-22T09:00:21Z
dc.date.issued2018-10-01none
dc.identifier.other10.1093/jac/dky386
dc.identifier.urihttp://edoc.rki.de/176904/6026
dc.description.abstractBackground The ability of MDR Gram-negative bacteria to evade even antibiotics of last resort is a severe global challenge. The development pipeline for conventional antibiotics cannot address this issue, but antimicrobial peptides (AMPs) offer an alternative solution. Objectives Two insect-derived AMPs (LS-sarcotoxin and LS-stomoxyn) were profiled to assess their suitability for systemic application in humans. Methods The peptides were tested against an extended panel of 114 clinical MDR Gram-negative bacterial isolates followed by time–kill analysis, interaction studies and assays to determine the likelihood of emerging resistance. In further in vitro studies we addressed cytotoxicity, cardiotoxicity and off-target interactions. In addition, an in vivo tolerability and pharmacokinetic study in mice was performed. Results LS-sarcotoxin and LS-stomoxyn showed potent and selective activity against Gram-negative bacteria and no cross-resistance with carbapenems, fluoroquinolones or aminoglycosides. Peptide concentrations of 4 or 8 mg/L inhibited 90% of the clinical MDR isolates of Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii and Salmonella enterica isolates tested. The ‘all-d’ homologues of the peptides displayed markedly reduced activity, indicating a chiral target. Pharmacological profiling revealed a good in vitro therapeutic index, no cytotoxicity or cardiotoxicity, an inconspicuous broad-panel off-target profile, and no acute toxicity in mice at 10 mg/kg. In mouse pharmacokinetic experiments LS-sarcotoxin and LS-stomoxyn plasma levels above the lower limit of quantification (1 and 0.25 mg/mL, respectively) were detected after 5 and 15 min, respectively. Conclusions LS-sarcotoxin and LS-stomoxyn are suitable as lead candidates for the development of novel antibiotics; however, their pharmacokinetic properties need to be improved for systemic administration.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectantibioticseng
dc.subjectGram-negative bacteriaeng
dc.subjectinsectaeng
dc.subjectpeptideseng
dc.subjectplasmaeng
dc.subjectmiceeng
dc.subjectpharmacokineticseng
dc.subjectpharmacologyeng
dc.subjectantimicrobialseng
dc.subjectcytotoxicityeng
dc.subjecttoxic effecteng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleProfiling antimicrobial peptides from the medical maggot Lucilia sericata as potential antibiotics for MDR Gram-negative bacterianone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6026-6
dc.identifier.doihttp://dx.doi.org/10.25646/5991
dc.type.versionpublishedVersionnone
local.edoc.container-titleJournal of Antimicrobial Chemotherapynone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://academic.oup.com/jac/article/74/1/96/5113243none
local.edoc.container-publisher-nameOxford University Pressnone
local.edoc.container-volume74none
local.edoc.container-issue1none
local.edoc.container-reportyear2018none
local.edoc.container-year2018none
local.edoc.container-firstpage96none
local.edoc.container-lastpage107none
local.edoc.rki-departmentInfektionskrankheitennone
dc.description.versionPeer Reviewednone

Show simple item record